1,3,5-triazine-2,4,6-triamine compound or pharmaceutical acceptable salt thereof, and pharmaceutical composition comprising the same

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 8722674
APP PUB NO 20110237587A1
SERIAL NO

12674886

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

Disclosed herein are a 1,3,5-triazine-2,4,6-triamine compound or a pharmaceutically acceptable salt thereof, a preparation method thereof, and a composition for preventing or treating metabolic syndromes, diabetes, or cancers with deletion of P53 gene, which comprises the same.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
HANALL BIOPHARMA CO LTD400-1 SANGSEO-DONG DAEDEOK-GU DAEJEON 306-120

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Cheon, Hyae Gyeong Daejeon, KR 16 56
Jun, Sung Soo Seongnam-si, KR 39 261
Jung, Won Hoon Daejeon, KR 12 52
Kim, Kwang-Rok Daejeon, KR 5 3
Kim, Sung Wuk Seongnam-si, KR 51 282
Lee, Jong-Cheol Daejeon, KR 68 1845
Rhee, Sang Dal Daejeon, KR 17 54

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
11.5 Year Payment $7400.00 $3700.00 $1850.00 Nov 13, 2025
Fee Large entity fee small entity fee micro entity fee
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00